Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOQ1VGX3BsbGNLQnZJRXBEeURjdmVpS2p0OVM2NDhpRnZMVElONjhQTnBuUHc1azFUdEJMN1JKc01IZTdiX0ZNME5sZmFYUVJVY0UtRWg5eTRyVHZBT182Z2h4LTNNOTd5cTVrWF9rTjBIVU5UWUVMWGxsZXJUVHE3XzV1WWlkYmpMUGo1MHc3WmpYc0Q4UEg0Ykl1eU5rbnRFNGZCZFlncmhGZHJicElPZXBJX3dJRVk?oc=5" target="_blank">Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMHalozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PMTeva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMUS FDA approves Asahi Kasei's drug for persistent herpes infections - Reuters
US FDA approves Asahi Kasei's drug for persistent herpes infections Reuters
October 9, 2026 at 06:01 PM